Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
May 29  •  04:00PM ET
8.53
Dollar change
-2.66
Percentage change
-23.77
%
May 29, 1:02 PMResale registration of 4.94M PIPE shares sparks dilution-driven 23% CODX plunge
Index
-
P/E
-
EPS (ttm)
-28.01
Insider Own
4.98%
Shs Outstand
3.60M
Perf Week
129.92%
Market Cap
30.73M
Forward P/E
-
EPS next Y
-
Insider Trans
0.00%
Shs Float
3.42M
Perf Month
457.52%
Enterprise Value
24.53M
PEG
-
EPS next Q
-
Inst Own
1.40%
Perf Quarter
270.87%
Income
-48.50M
P/S
60.25
EPS this Y
-
Inst Trans
-6.52%
Perf Half Y
-12.51%
Sales
0.51M
P/B
1.92
EPS next Y
-
ROA
-126.56%
Perf YTD
68.64%
Book/sh
4.45
P/C
3.73
EPS next 5Y
-
ROE
-151.66%
52W High
46.50 -81.66%
Perf Year
-1.27%
Cash/sh
2.28
P/FCF
-
EPS past 3/5Y
-37.47% -
ROIC
-281.74%
52W Low
1.26 576.98%
Perf 3Y
-73.67%
Dividend Est.
-
EV/EBITDA
-
Sales past 3/5Y
-76.97% -64.54%
Gross Margin
-187.30%
Volatility
70.30% 35.53%
Perf 5Y
-96.48%
Dividend TTM
-
EV/Sales
48.10
EPS Y/Y TTM
18.03%
Oper. Margin
-6255.15%
ATR (14)
1.92
Perf 10Y
-
Dividend Ex-Date
-
Quick Ratio
2.09
Sales Y/Y TTM
-9.46%
Profit Margin
-9438.49%
RSI (14)
66.76
Dividend Gr. 3/5Y
- -
Current Ratio
2.28
EPS Q/Q
42.48%
SMA20
145.17%
Beta
3.21
Payout
-
Debt/Eq
0.13
Sales Q/Q
190.30%
SMA50
252.48%
Rel Volume
0.51
Prev Close
11.19
Employees
115
LT Debt/Eq
0.07
SMA200
28.34%
Avg Volume
6.47M
Price
8.53
IPO
Jul 12, 2017
Option/Short
No / Yes
Trades
Volume
3,326,489
Change
-23.77%
May-26-26 01:00PM
09:00AM
May-19-26 10:54PM
10:34AM
May-15-26 08:30AM
01:02AM Loading…
01:02AM
May-14-26 04:01PM
May-11-26 05:43AM
May-08-26 09:00AM
Apr-16-26 09:00AM
Apr-14-26 09:00AM
Apr-09-26 09:00AM
Apr-02-26 09:00AM
Apr-01-26 08:30AM
Mar-31-26 11:02PM
04:01PM Loading…
04:01PM
Mar-25-26 08:00AM
Mar-20-26 03:30PM
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
ChairmanMr. Dwight H. Egan
PresidentMr. Richard David Abbott
CFO & Company SecretaryMr. Brian L. Brown CPA
Chief Operating OfficerMr. David Nielsen
Vice President of Finance & AccountingMr. Dan Bohrer CPA